Visioneering Technologies, Inc. (VTI.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.76 Million AUD | -1.64% |
| 2022 | 2.81 Million USD | -42.23% |
| 2021 | 4.86 Million AUD | -27.24% |
| 2020 | 6.69 Million AUD | 38.04% |
| 2019 | 4.84 Million AUD | 242.86% |
| 2018 | 1.41 Million AUD | 3.29% |
| 2017 | 1.36 Million AUD | 233.9% |
| 2016 | 410 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.76 Million USD | -6.3% |
| 2024 Q2 | 1.76 Million USD | 0.0% |
| 2023 Q4 | 1.88 Million USD | -35.72% |
| 2023 Q2 | 5.31 Million USD | 0.37% |
| 2023 FY | 2.76 Million AUD | -1.64% |
| 2023 Q1 | 5.29 Million USD | 88.24% |
| 2023 Q3 | 2.93 Million USD | -44.74% |
| 2022 Q2 | 6.4 Million USD | 8.39% |
| 2022 Q4 | 2.81 Million USD | -36.04% |
| 2022 FY | 2.81 Million USD | -42.23% |
| 2022 Q1 | 5.91 Million USD | 21.42% |
| 2022 Q3 | 4.39 Million USD | -31.36% |
| 2021 Q1 | 9.76 Million USD | 12.43% |
| 2021 FY | 4.86 Million AUD | -27.24% |
| 2021 Q4 | 4.86 Million AUD | -27.74% |
| 2021 Q3 | 6.73 Million USD | -31.91% |
| 2021 Q2 | 9.89 Million USD | 1.3% |
| 2020 Q4 | 8.68 Million AUD | -7.05% |
| 2020 FY | 6.69 Million AUD | 38.04% |
| 2020 Q1 | 9.09 Million USD | 87.67% |
| 2020 Q2 | 8.1 Million USD | -10.89% |
| 2020 Q3 | 9.34 Million USD | 15.3% |
| 2019 Q4 | 4.84 Million AUD | -32.51% |
| 2019 FY | 4.84 Million AUD | 242.86% |
| 2019 Q3 | 7.18 Million USD | 216.16% |
| 2019 Q2 | 2.27 Million USD | 1.14% |
| 2019 Q1 | 2.24 Million USD | 58.87% |
| 2018 Q1 | 2.32 Million USD | 69.53% |
| 2018 Q3 | 1.9 Million USD | -20.97% |
| 2018 Q4 | 1.41 Million AUD | -25.73% |
| 2018 FY | 1.41 Million AUD | 3.29% |
| 2018 Q2 | 2.4 Million USD | 3.8% |
| 2017 Q2 | 1.2 Million USD | -0.6% |
| 2017 Q1 | 1.21 Million USD | -96.61% |
| 2017 FY | 1.36 Million AUD | 233.9% |
| 2017 Q4 | 1.36 Million AUD | -19.76% |
| 2017 Q3 | 1.7 Million USD | 41.15% |
| 2016 FY | 410 Thousand AUD | 0.0% |
| 2016 Q4 | 35.9 Million USD | 6.07% |
| 2016 Q3 | 33.85 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 4DMedical Limited | 49.08 Million AUD | 94.363% |
| Adherium Limited | 3.4 Million AUD | 18.782% |
| Aroa Biosurgery Limited | 14.77 Million AUD | 81.278% |
| Atomo Diagnostics Limited | 1.29 Million AUD | -113.761% |
| Anteris Technologies Ltd | 17.03 Million AUD | 83.761% |
| Control Bionics Limited | 2.75 Million AUD | -0.265% |
| CardieX Limited | 8.56 Million AUD | 67.685% |
| Compumedics Limited | 22.14 Million AUD | 87.507% |
| Cochlear Limited | 904.6 Million AUD | 99.694% |
| CleanSpace Holdings Limited | 6.94 Million AUD | 60.187% |
| Cyclopharm Limited | 13.65 Million AUD | 79.737% |
| EMVision Medical Devices Ltd | 5.45 Million AUD | 49.284% |
| Nova Eye Medical Limited | 8.55 Million AUD | 67.646% |
| HeraMED Limited | 1.5 Million AUD | -83.733% |
| Imricor Medical Systems, Inc. | 25 Million AUD | 88.934% |
| ImpediMed Limited | 6.24 Million AUD | 55.68% |
| InhaleRx Limited | 911.41 Thousand AUD | -203.585% |
| LBT Innovations Limited | 5.5 Million AUD | 49.766% |
| Micro-X Limited | 12.63 Million AUD | 78.1% |
| Neurotech International Limited | 314.69 Thousand AUD | -779.224% |
| OncoSil Medical Limited | 1.98 Million AUD | -39.602% |
| PolyNovo Limited | 37.04 Million AUD | 92.531% |
| Respiri Limited | 3.55 Million AUD | 22.146% |
| SomnoMed Limited | 24.78 Million AUD | 88.834% |
| Universal Biosensors, Inc. | 10.61 Million AUD | 73.928% |
| Uscom Limited | 2.07 Million AUD | -33.437% |